Agios Pharmaceuticals (AGIO)

$35.20 +1.01 (2.95%)
Market Cap 2.06B
Revenue (ttm) 54.03M
Net Income (ttm) -412.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -763.98%
Debt to Equity Ratio 0.00
Volume 1,425,400
Avg Vol 920,666
Day's Range N/A - N/A
Shares Out 58.59M
Stochastic %K 87%
Beta 0.79
Analysts Strong Sell
Price Target $41.50

Company Profile

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pedi...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 649 8600
Address:
88 Sidney Street, Cambridge, United States
stu4
stu4 Apr. 3 at 9:51 PM
$AGIO $AIRO Agio is dog shit, plane an simple 50% lower in 7 years …that’s deplorable. And yet, the company has NOT FIRED , the usless BRASS It is white collar welfare
1 · Reply
WallStreetBuyDip
WallStreetBuyDip Apr. 3 at 9:47 PM
Comparing trending tickers $AIRO vs $AGIO: AIRO is up 5.96% to $8.71 on a volume of 639.0K shares, which is below its average of 1.0M. AGIO, on the other hand, has increased by 2.95% to $35.20, with a trading volume of 1.4M shares, surpassing its typical 959.1K. Despite both stocks trending upwards, AIRO shows a more significant percentage increase, while AGIO displays stronger trading activity, exceeding its average volume.
0 · Reply
ClenchFists
ClenchFists Apr. 3 at 6:15 PM
$AGIO Unreal
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 3 at 5:36 PM
The attachment notes the 22 commercial-stage bios trading within 10% of their highest closing share price since 12/1/2025 as of 4/2/2026. We count 89 such bios in total in this peer group (25 oncology focused with MCs over $300MM & 64 non-oncology focused with MCs over $800MM). $RPRX $KNSA $AGIO & $TGTX are the non-oncology bios in this peer group all trading at their highest share prices since 12/1/2025. $SNDX closed at its highest closing price in oncology. Thank you Goldman Sachs. SNDX investors may want to look at SNDX trading after Goldman's last upgrade that, our records reflect, was issued on 9/5/25. This is not investment advice.
1 · Reply
erevnon
erevnon Apr. 1 at 6:20 PM
Goldman Sachs maintains Agios Pharmaceuticals $AGIO at Neutral and raises the price target from $28 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
fallondpicks
fallondpicks Mar. 31 at 9:22 PM
11 #stockbreakouts $AGIO (200-day MA and Base), $ALKS (gap), $UNIT (gap). One $1-2.
0 · Reply
stu4
stu4 Mar. 31 at 8:45 PM
$AGIO Hahaha …watchers went up by 3 Woooo hooooo. Goff and Fouse have fcuked everyone on the street with innuendos and lies .
0 · Reply
stu4
stu4 Mar. 31 at 8:43 PM
$AGIO you have , true. BUT even MAGA’s were warned , that TRUMP had project 2025 on the agenda , and the low iq , uneducated and degenerate educated , and the farmers he fcuked his first tern, couldn’t be convinced otherwise … So, poor @phatsuit , thought that it would be different just for him , and Like the farmers , He Bought into Hell , AGIOS
0 · Reply
Dkll303
Dkll303 Mar. 31 at 8:39 PM
$AGIO oh boy ……here , remember this : 🎹🎶🎵🎹“A KISS IS BUT A KISS , A SIGH IS BUT A SIGH 🎵🎶🎵🎹🎶🎵🎶🎹🎹🎹🎹🎹🎶🎵🎹🎶🎵🎶 “ IT’S STILL THE SAME OLD STORY “” WHEN PIGS WILL FLY @Marketmover888 ..Warren , please Clearly , you are clueless as to the misfit biotech senior execs that run this welfare office for “ the less fortunate “ It is worse that the Minnesota Fraud , uncovered !!!!
0 · Reply
Dkll303
Dkll303 Mar. 31 at 8:30 PM
$AGIO I’ve posted enough to warn people of this mgmt team , NONE are scientists. Just hack middle managers , laid off in the biotech world , never successful at any level . You didn’t read my posts @phatsuit
0 · Reply
Latest News on AGIO
PK Activation Gains Momentum in Thalassemia Agios' Aqvesme Launch Reflects Strong Promise with Deliberate Uptake

Mar 31, 2026, 8:45 AM EDT - 4 days ago

PK Activation Gains Momentum in Thalassemia Agios' Aqvesme Launch Reflects Strong Promise with Deliberate Uptake

Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA

Mar 31, 2026, 7:00 AM EDT - 4 days ago

Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA

Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates

Mar 2, 2026, 7:00 AM EST - 4 weeks ago

Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates

Agios Pharmaceuticals, Inc. (AGIO) Q4 2025 Earnings Call Transcript

Feb 12, 2026, 5:04 PM EST - 7 weeks ago

Agios Pharmaceuticals, Inc. (AGIO) Q4 2025 Earnings Call Transcript

Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 12, 2026, 6:30 AM EST - 7 weeks ago

Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET

Jan 26, 2026, 7:00 AM EST - 2 months ago

Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET

Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 2:36 PM EST - 2 months ago

Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth

Jan 12, 2026, 7:00 AM EST - 2 months ago

Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth

Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Jan 5, 2026, 7:00 AM EST - 3 months ago

Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript

Dec 24, 2025, 4:56 PM EST - 3 months ago

Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript

Agios Pharma Stock: A Buy After FDA Approves Aqvesme

Dec 24, 2025, 12:48 PM EST - 3 months ago

Agios Pharma Stock: A Buy After FDA Approves Aqvesme

Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat

Dec 24, 2025, 9:56 AM EST - 3 months ago

Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat

Agios Pharma shares jump as US FDA expands approval for its blood disorder drug

Dec 24, 2025, 8:22 AM EST - 3 months ago

Agios Pharma shares jump as US FDA expands approval for its blood disorder drug

U.S. FDA Approves Agios' AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

Dec 23, 2025, 7:45 PM EST - 3 months ago

U.S. FDA Approves Agios' AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia

Dec 8, 2025, 7:00 AM EST - 4 months ago

Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia

Agios Pharmaceuticals, Inc. (AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease Transcript

Nov 19, 2025, 2:33 PM EST - 4 months ago

Agios Pharmaceuticals, Inc. (AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease Transcript

Why Is Agios Pharmaceuticals Stock Sinking Today?

Nov 19, 2025, 12:30 PM EST - 4 months ago

Why Is Agios Pharmaceuticals Stock Sinking Today?

Agios Pharma reports mixed results in late-stage study for sickle cell disease drug

Nov 19, 2025, 8:24 AM EST - 4 months ago

Agios Pharma reports mixed results in late-stage study for sickle cell disease drug

Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease

Nov 19, 2025, 7:00 AM EST - 4 months ago

Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease

Q3 2025 Highlights - Agios Posts Strong Pyrukynd Revenue And Eyes FDA Milestones

Nov 4, 2025, 1:47 AM EST - 5 months ago

Q3 2025 Highlights - Agios Posts Strong Pyrukynd Revenue And Eyes FDA Milestones

Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition

Nov 3, 2025, 9:01 AM EST - 5 months ago

Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. (AGIO) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 2:06 PM EDT - 5 months ago

Agios Pharmaceuticals, Inc. (AGIO) Q3 2025 Earnings Call Transcript

Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 30, 2025, 6:30 AM EDT - 5 months ago

Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

Avanzanite Bioscience's Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia

Oct 17, 2025, 8:15 AM EDT - 6 months ago

Avanzanite Bioscience's Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia

Agios' PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia

Oct 17, 2025, 8:00 AM EDT - 6 months ago

Agios' PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia

Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET

Oct 16, 2025, 7:00 AM EDT - 6 months ago

Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET

AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

Sep 18, 2025, 5:49 AM EDT - 7 months ago

AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation With the Schall Law Firm

Sep 15, 2025, 12:20 PM EDT - 7 months ago

AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation With the Schall Law Firm

Agios Pharmaceuticals: Why A Delayed FDA Review Could Still Be A Positive

Sep 8, 2025, 10:32 AM EDT - 7 months ago

Agios Pharmaceuticals: Why A Delayed FDA Review Could Still Be A Positive

Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be Mitigated

Sep 4, 2025, 12:46 PM EDT - 7 months ago

Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be Mitigated

FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use

Sep 4, 2025, 10:49 AM EDT - 7 months ago

FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia

Sep 4, 2025, 7:00 AM EDT - 7 months ago

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia

Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

Aug 4, 2025, 4:01 PM EDT - 8 months ago

Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

Agios Pharmaceuticals, Inc. (AGIO) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 5:02 PM EDT - 8 months ago

Agios Pharmaceuticals, Inc. (AGIO) Q2 2025 Earnings Call Transcript

Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 6:30 AM EDT - 8 months ago

Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET

Jul 14, 2025, 7:00 AM EDT - 9 months ago

Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET

Agios Appoints Dr. Jay Backstrom to Board of Directors

Jul 8, 2025, 7:00 AM EDT - 9 months ago

Agios Appoints Dr. Jay Backstrom to Board of Directors

Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders

Jun 9, 2025, 8:40 AM EDT - 10 months ago

Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders

Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025

May 28, 2025, 7:00 AM EDT - 11 months ago

Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025

Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress

May 14, 2025, 10:00 AM EDT - 11 months ago

Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress

Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025

May 9, 2025, 7:00 AM EDT - 11 months ago

Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025

Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025

May 2, 2025, 7:00 AM EDT - 1 year ago

Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025

Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call Transcript

May 1, 2025, 12:06 PM EDT - 1 year ago

Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call Transcript

stu4
stu4 Apr. 3 at 9:51 PM
$AGIO $AIRO Agio is dog shit, plane an simple 50% lower in 7 years …that’s deplorable. And yet, the company has NOT FIRED , the usless BRASS It is white collar welfare
1 · Reply
WallStreetBuyDip
WallStreetBuyDip Apr. 3 at 9:47 PM
Comparing trending tickers $AIRO vs $AGIO: AIRO is up 5.96% to $8.71 on a volume of 639.0K shares, which is below its average of 1.0M. AGIO, on the other hand, has increased by 2.95% to $35.20, with a trading volume of 1.4M shares, surpassing its typical 959.1K. Despite both stocks trending upwards, AIRO shows a more significant percentage increase, while AGIO displays stronger trading activity, exceeding its average volume.
0 · Reply
ClenchFists
ClenchFists Apr. 3 at 6:15 PM
$AGIO Unreal
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 3 at 5:36 PM
The attachment notes the 22 commercial-stage bios trading within 10% of their highest closing share price since 12/1/2025 as of 4/2/2026. We count 89 such bios in total in this peer group (25 oncology focused with MCs over $300MM & 64 non-oncology focused with MCs over $800MM). $RPRX $KNSA $AGIO & $TGTX are the non-oncology bios in this peer group all trading at their highest share prices since 12/1/2025. $SNDX closed at its highest closing price in oncology. Thank you Goldman Sachs. SNDX investors may want to look at SNDX trading after Goldman's last upgrade that, our records reflect, was issued on 9/5/25. This is not investment advice.
1 · Reply
erevnon
erevnon Apr. 1 at 6:20 PM
Goldman Sachs maintains Agios Pharmaceuticals $AGIO at Neutral and raises the price target from $28 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
fallondpicks
fallondpicks Mar. 31 at 9:22 PM
11 #stockbreakouts $AGIO (200-day MA and Base), $ALKS (gap), $UNIT (gap). One $1-2.
0 · Reply
stu4
stu4 Mar. 31 at 8:45 PM
$AGIO Hahaha …watchers went up by 3 Woooo hooooo. Goff and Fouse have fcuked everyone on the street with innuendos and lies .
0 · Reply
stu4
stu4 Mar. 31 at 8:43 PM
$AGIO you have , true. BUT even MAGA’s were warned , that TRUMP had project 2025 on the agenda , and the low iq , uneducated and degenerate educated , and the farmers he fcuked his first tern, couldn’t be convinced otherwise … So, poor @phatsuit , thought that it would be different just for him , and Like the farmers , He Bought into Hell , AGIOS
0 · Reply
Dkll303
Dkll303 Mar. 31 at 8:39 PM
$AGIO oh boy ……here , remember this : 🎹🎶🎵🎹“A KISS IS BUT A KISS , A SIGH IS BUT A SIGH 🎵🎶🎵🎹🎶🎵🎶🎹🎹🎹🎹🎹🎶🎵🎹🎶🎵🎶 “ IT’S STILL THE SAME OLD STORY “” WHEN PIGS WILL FLY @Marketmover888 ..Warren , please Clearly , you are clueless as to the misfit biotech senior execs that run this welfare office for “ the less fortunate “ It is worse that the Minnesota Fraud , uncovered !!!!
0 · Reply
Dkll303
Dkll303 Mar. 31 at 8:30 PM
$AGIO I’ve posted enough to warn people of this mgmt team , NONE are scientists. Just hack middle managers , laid off in the biotech world , never successful at any level . You didn’t read my posts @phatsuit
0 · Reply
Dkll303
Dkll303 Mar. 31 at 8:28 PM
$AGIO Smart guy ,ahhh, you don’t want to be like Bellevenue LTD , dumping Nov 19 2025 after 7 years of FOUSE the fcuker, lying , they took a 40M dollar loss ….Consider your loss , a brighter move !!! Since mgmt is tha fcuked up, and they lie lie lie. They picked that up from the old CEO David Schenkien, a lab rat from millennial Pharma with no business skills .
0 · Reply
Few_erish
Few_erish Mar. 31 at 7:47 PM
$AGIO not as weak as bears wanted
0 · Reply
phatsuit
phatsuit Mar. 31 at 7:47 PM
$AGIO Dumped it for a $200 loss...fuck it
0 · Reply
Dkll303
Dkll303 Mar. 31 at 6:16 PM
$AGIO don’t bother , mgmt sucks , it is a welfare office for misfits in the biotech field
1 · Reply
Dkll303
Dkll303 Mar. 31 at 6:15 PM
$AGIO of course he would , he is the marketing director, no skin in the game, just a leach , Krishnan , but was sold last week on the Morgan Stanley CHURN , higher MS does that for these misfits , cause they can’t create value , hahaha
0 · Reply
LewisDaKat
LewisDaKat Mar. 31 at 5:31 PM
$AGIO Why Agios Pharmaceuticals Stock Is Up More Than 21% Today https://marketwirenews.com/stock/agio/news/why-agios-pharmaceuticals-stock-is-up-more-than-21-t-8732564732700925.html?utm_source=stocktwits
0 · Reply
LewisDaKat
LewisDaKat Mar. 31 at 5:00 PM
$AGIO Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything https://marketwirenews.com/stock/agio/news/insider-sells-agio-shares-worth-82-000-but-context-i-7951200050896189.html?utm_source=stocktwits
0 · Reply
phatsuit
phatsuit Mar. 31 at 3:54 PM
$AGIO I'll try!
0 · Reply
notreload_ai
notreload_ai Mar. 31 at 3:12 PM
$AGIO is pursuing accelerated FDA approval for mitapivat, a new oral pill for sickle cell disease. The RISE UP trial showed better hemoglobin levels, fewer pain crises, and good safety. https://notreload.xyz/xy/agios-moves-closer-to-fast-fda-approval-for-sickle-cell-pill/
0 · Reply
Marketmover888
Marketmover888 Mar. 31 at 3:12 PM
$AGIO will close today over $50
0 · Reply
sprasad03
sprasad03 Mar. 31 at 2:06 PM
$AGIO This will be close above $36 today
0 · Reply
MaverikIT
MaverikIT Mar. 31 at 1:58 PM
$KYMR $AGIO +5.46 - LFG
0 · Reply